#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10284	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2287	446.1	0	.	n	.	0	C450T	SNP	450	450	C	847	847	T	552	T,C,G	488,3,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10284	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2287	446.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1847	1847	T	560	T	523	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10284	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2287	446.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1581	1581	C	602	C,A	583,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10284	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2287	446.1	0	HET	.	.	.	A69G	.	69	69	A	466	466	A	522	A,G	309,201	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10284	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2287	446.1	0	HET	.	.	.	C207T	.	207	207	C	604	604	C	565	C,T	330,195	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10284	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2287	446.1	0	HET	.	.	.	G213A	.	213	213	G	610	610	G	552	G,A	434,98	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19628	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3582	544.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1700	1700	A	651	A,T	640,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19628	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3582	544.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2334	2334	C	571	C	554	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19628	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3582	544.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2408	2408	A	590	A	579	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19628	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3582	544.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2960	2960	C	554	C	540	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	1298	folP	852	852	99.88	folP.l15.c4.ctg.1	1520	84.5	0	.	p	.	0	E151K	NONSYN	451	453	GAA	759	761	AAA	126;127;126	A;A;A	124;125;126	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	1298	folP	852	852	99.88	folP.l15.c4.ctg.1	1520	84.5	1	SNP	p	R228S	1	.	.	682	684	AGC	990	992	AGC	128;129;129	A;G;C	125;127;124	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3400	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3541	95.4	1	SNP	p	S91F	0	.	.	271	273	TCC	620	622	TCC	119;118;117	T;C;C,A	116;114;113,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3400	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3541	95.4	1	SNP	p	D95G	0	.	.	283	285	GAC	632	634	GAC	120;121;121	G;A;C	115;113;119	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3400	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3541	95.4	1	SNP	p	D95N	0	.	.	283	285	GAC	632	634	GAC	120;121;121	G;A;C	115;113;119	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1162	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1562	73.9	0	.	p	.	0	D79N	NONSYN	235	237	GAT	694	696	AAT	119;118;120	A;A;T	119;115;118	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1162	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1562	73.9	1	SNP	p	G45D	0	.	.	133	135	GGC	592	594	GGC	130;129;126	G;G;C	127;125;122	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	650	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	957	66.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3054	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2924	103.5	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1677	1679	GCA	130;128;130	G;C;A	126;121;117	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3054	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2924	103.5	1	SNP	p	D86N	0	.	.	256	258	GAC	630	632	GAC	126;129;129	G,A;A;C,A	117,1;121;123,1	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3054	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2924	103.5	1	SNP	p	S87I	0	.	.	259	261	AGT	633	635	AGT	127;126;126	A;G;T	118;123;117	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3054	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2924	103.5	1	SNP	p	S87R	0	.	.	259	261	AGT	633	635	AGT	127;126;126	A;G;T	118;123;117	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3054	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2924	103.5	1	SNP	p	S87W	0	.	.	259	261	AGT	633	635	AGT	127;126;126	A;G;T	118;123;117	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3054	parC	2304	2304	99.78	parC.l15.c4.ctg.1	2924	103.5	1	SNP	p	S88P	0	.	.	262	264	TCC	636	638	TCC	127;124;124	T,C;C;C	120,2;121;118	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2744	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2656	101.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1611	1613	GGC	146;145;143	G;G;C	144;143;132	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	539	2752	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2430	112.4	1	SNP	p	A502V	1	A502V	NONSYN	1504	1506	GCG	1827	1829	GTG	147;141;144	G;T,G;G	138;104,9;136	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	2752	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2430	112.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1254	1256	GCA	133;135;137	G;C;A	128;128;132	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	2752	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2430	112.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1257	1259	ATC	136;136;133	A;T;C	134;131;129	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	2752	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2430	112.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1269	1271	GTG	142;144;146	G;T;G,A	137;134;140,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	2752	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2430	112.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1269	1271	GTG	142;144;146	G;T;G,A	137;134;140,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	2752	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2430	112.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1773	1775	ACC	146;146;146	A,C;C;C	132,1;138;140	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	2752	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2430	112.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1950	1952	GGC	109;109;109	G;G;C	108;105;104	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	2752	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2430	112.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1959	1961	GGC	107;106;106	G;G;C	101;102;98	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	2752	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2430	112.4	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1977	1979	CTG	100;100;97	C,G;T;G	87,3;87;82	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4158	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3131	132.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1613	1615	CCG	150;151;149	C;C;G	141;149;140	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1492	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1943	76.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	717	717	C	92	C,A	86,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	E41Q	NONSYN	121	123	GAA	366	368	CAA	133;131;133	C;A;A,C	127;130;131,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	T89S	NONSYN	265	267	ACC	510	512	AGC	150;146;145	A;G;C	140;139;135	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	T106I	NONSYN	316	318	ACC	561	563	ATC	127;126;124	A,C;T;C	119,2;120;117	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	.	MULTIPLE	358	359	AA	602	603	CG	125;122	C;G	123;118	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	.	MULTIPLE	361	362	GA	605	607	CAG	125;126;126	C;A;G	120;123;124	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	N122K	NONSYN	364	366	AAC	609	611	AAA	130;129;131	A;A;A	126;124;128	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	636	638	TAT	141;139;138	T;A;T	139;137;134	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	N134E	NONSYN	400	402	AAT	645	647	GAG	140;144;145	G;A;G	140;143;144	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	V135F	NONSYN	403	405	GTG	648	650	TTT	147;146;147	T;T;T	137;145;145	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	G140K	NONSYN	418	420	GGA	663	665	AAA	146;148;151	A;A;A	142;144;148	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	K143E	NONSYN	427	429	AAA	672	674	GAA	153;154;157	G;A,C;A	146;148,1;149	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	V151A	NONSYN	451	453	GTA	696	698	GCA	153;152;155	G;C;A	152;150;150	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	804	806	CAA	153;154;154	C;A;A	150;150;153	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	N189S	NONSYN	565	567	AAC	810	812	AGC	165;163;164	A;G;C	156;155;159	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	T213L	NONSYN	637	639	ACA	882	884	TTA	183;185;184	T;T;A,T	179;180;178,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	A244V	NONSYN	730	732	GCA	975	977	GTA	148;147;148	G,A;T;A	144,1;139;145	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1002	1004	CAA	145;143;144	C;A;A	143;141;142	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	.	INDELS	760	762	ACA	1006	1010	ATCAA	143;144;144;143;143	A;T;C;A;A	141;140;144;143;143	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	.	INDELS	763	764	TG	1013	1015	AGT	146;147;147	A;G;T	145;146;142	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1020	1022	GAT	145;144;142	G,C;A;T	143,1;142;142	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	V270A	NONSYN	808	810	GTA	1059	1061	GCG	148;148;153	G;C;G	144;143;148	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1128	1130	AGT	160;163;161	A;G;T,G	158;156;151,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	1	SNP	p	G120K	1	.	.	358	360	AAG	602	604	CGG	125;122;125	C;G;G	123;118;121	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	1	SNP	p	A121D	1	.	.	361	363	GAC	605	608	CGC	125;126;126	C;G;C	120;124;120	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1950	porB1b	1041	1041	95.99	porB1b.l15.c17.ctg.1	1519	127.3	1	SNP	p	D121N	0	.	.	361	363	GAC	605	608	CGC	125;126;126	C;G;C	120;124;120	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	7682	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4740	161.1	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1937	1939	CAT	165;163;166	C;A;T	161;160;161	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	924	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1017	89.6	1	SNP	p	V57M	1	.	.	169	171	ATG	521	523	ATG	184;186;186	A;T;G	180;181;180	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
